Ruxolitinib cream + Vehicle
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hand Eczema
Conditions
Hand Eczema
Trial Timeline
Jul 31, 2023 → Dec 13, 2024
NCT ID
NCT05906628About Ruxolitinib cream + Vehicle
Ruxolitinib cream + Vehicle is a phase 2 stage product being developed by Incyte for Hand Eczema. The current trial status is completed. This product is registered under clinical trial identifier NCT05906628. Target conditions include Hand Eczema.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05906628 | Phase 2 | Completed |
| NCT05219864 | Phase 3 | Withdrawn |
| NCT05233410 | Phase 3 | Withdrawn |
| NCT05127421 | Phase 2 | Completed |
| NCT04057573 | Phase 3 | Completed |
| NCT04052425 | Phase 3 | Completed |
Competing Products
17 competing products in Hand Eczema
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lebrikizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Methylprednisolone Tablet | Johnson & Johnson | Phase 2/3 | 65 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Pimecrolimus Cream 1% | Novartis | Phase 3 | 77 |
| tocilizumab + saline solution | Roche | Phase 3 | 77 |
| denosumab + Placebo | Amgen | Phase 2 | 51 |
| Dupilumab + Placebo | Sanofi | Phase 2 | 51 |
| dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| clobetasol propionate | GSK plc | Approved | 84 |
| urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smooth® Udder Cream) | Bayer | Phase 2 | 49 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| Ruxolitinib | Incyte | Phase 1/2 | 38 |
| Ruxolitinib cream + Vehicle | Incyte | Phase 3 | 74 |
| ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle Cream | Arcutis Biotherapeutics | Phase 1/2 | 36 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |
| alitretinoin | Basilea Pharmaceutica | Phase 3 | 72 |